Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

Michael J. Sorich; Thomas M. Polasek; Michael D. Wiese

doi:10.1160/TH12-02-0095

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(01): 199-200
DOI: 10.1160/TH12-02-0095

Letter to the Editor

Schattauer GmbH

Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

Authors

Michael J. Sorich

¹School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia
Thomas M. Polasek

²Department of Clinical Pharmacology, Flinders University School of Medicine, Adelaide, South Australia, Australia
Michael D. Wiese

¹School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia

Abstract

Full Text

References

References
1 Bowry ADK. et al. Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. Am J Cardiol 2008; 101: 960-966.
2 Scott SA. et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90: 328-332.
3 Lu CY. et al. The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: A case study of prasugrel. Clin Pharmacol Ther 2011; 90: 27-29.
4 Sorich MJ. et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 08: 1678-1684.
5 Polasek TM. et al. Metabolic activation of clopidogrel:in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Therapeutic Advances in Drug Safety 2011; 02: 253-261.
6 Review Manager (RevMan). Version 5.1. 5.1 ed. The Nordic Cochrane Centre. The Cochrane Collaboration, Copenhagen. 2011
7 Bhatt DL. et al. Charisma Genomics Substudy: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention. Available at: http://www.clinicaltrialresults.org/Slides/CHARISMA%20Genomics.ppt Accessed January 24, 2012
8 Wallentin L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
9 Mega JL. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
10 Pare G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
11 Campo G. et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
12 Sibbing D. et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512-518.
13 Luo Y. et al. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res 2011; 39: 2012-2019.
14 Harmsze AM. et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
15 Zabalza M. et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-108.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)